Veraxa Biotech AG

Veraxa Biotech Holding AG operates in the biotechnology sector, focusing on microfluidics-based antibody screening technology. The company's business activities commenced upon the closing of a business combination where Veraxa Biotech AG merged into PubCo, with PubCo as the surviving entity. Veraxa Biotech Holding AG holds intellectual property, including patents relevant to its Hitmaster and microfluidics-based antibody screening technology. One key patent, titled "MICROFLUIDIC DROPLET DETECTION AND SORTING," describes a microfluidic system designed to detect and sort droplets containing particles labeled with detectable markers. This system identifies droplets based on the presence and intensity of these markers and directs them into different channels for sorting. The method also supports quantitative binding assays and high-throughput applications such as single-cell analysis, drug screening, and diagnostics. This patent was filed on 4/29/16 and is granted in Canada (CA2984045), China (CN107810413), Europe (EP3289362, with opposition rejected and in appeal), Hong Kong (HK1251660), Israel (IL255260), India (IN364123), Japan (JP6851982), and the USA (US10710078), with an expiration date of 4/29/36 in all these regions. The European patent is validated in AT, BE, CH, CZ, DE, DK, ES, FR, GB, IE, IT, LU, NL, PT, and SE. Another patent, titled "MICROFLUIDIC ANALYSIS OF LIGAND INDUCED CELL EXPRESSION," is also relevant for Veraxa's Hitmaster and microfluidics-based antibody screening technology. This patent describes a microfluidic system that analyzes cellular responses to ligands at the single-cell level. It encapsulates individual cells in microdroplets and exposes them to specific ligands to detect and quantify changes in gene expression. This method enables high-throughput, quantitative binding assays, facilitating applications in drug discovery and cellular biology research.